Patents by Inventor Jonathan Ogle

Jonathan Ogle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11969434
    Abstract: Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: April 30, 2024
    Inventors: Jonathan Ogle, Benjamin J. Bruno, Kongnara Papangkorn, Samuel Akapo, Joel Frank, Nachiappan Chidambaram, Mahesh V. Patel
  • Publication number: 20230390304
    Abstract: Disclosed is a method and composition for treating CNS disorders in a subject. In an embodiment, the method preferably comprises the ordered steps of identifying a subject having or being predisposed to epilepsy, and orally administering to the subject an AED. The administration preferably comprises an administration regimen of a predetermined quantity of the AED, at a predetermined frequency, and for a predetermined duration. The subject preferably comprises a subject experiencing seizure clusters, WWE, and more especially a WWE of childbearing age. The composition preferably comprises a NAS, and more especially an ENAS. The method preferably results in the prevention, or reduced frequency or magnitude of epileptic seizures.
    Type: Application
    Filed: June 2, 2023
    Publication date: December 7, 2023
    Applicant: Lipocine Inc.
    Inventors: Benjamin J. Bruno, Nachiappan Chidambaram, Jonathan Ogle, Kongnara Papangkorn, Mahesh V. Patel